The Challenge of Liver Toxicity
in Drug Development.
Testing Limitations (ALT / AST)
Traditional indicators lack specificity and are released by non-hepatic tissues, leading to false safety flags that incorrectly kill viable drug candidates.
PCR's Fatal Flaw: isomiRs
PCR cannot distinguish miRNA variants (isomiRs): degradation products that create false negatives. This renders PCR unreliable for clinical miRNA diagnostics.
Lost opportunities from false positive signals and late-stage failures due to hepatotoxicity
DILI is the leading cause of acute liver failure worldwide
LiverAce™ COMBO Kit
Multi-Omic. Single Platform.
LiverAce™ COMBO brings a protein biomarker and a miRNA biomarker of liver toxicity together on a single immunoassay platform, with PCR-free miRNA-122 and CK18 detection and quantification. Both miRNA-122 and CK18 are well established markers for liver toxicity/injury. miRNA-122 provides early assessment of liver toxicity/stress while CK18 identifies liver cell death. While elevated CK18 is a strong indicator of cell death, combining it with the earlier stress-related miRNA-122 biomarker ensures the damage is definitively tied to the liver. By overcoming the isomiR challenge and providing stage of injury (stress vs cell death) insights on one immunoassay platform, LiverAce™ COMBO delivers high value information towards drug development success and the avoidance of late-stage failures.
For Research Use Only
Not for use in diagnostic procedures
Complete drug development process
One assay for the complete drug development process. Provides accurate and reproducible assessment of drug toxicity across all stages, identifying toxicity problems early in the development lifecycle.
Diagnostic Sensitivity
Image adapted from Thulin et al. (2014) Liver Int.
Key Values
Scientific Proof
Key Publications (Biomarkers)
Clinical evidence supporting miR-122 and Keratin-18 as superior biomarkers for DILI.
Destina Chemistry (DGL-Tech)
Foundational papers on the Destina Chemistry that powers LiverAce™ assays.
Product Characteristics
Kit Specifications
| Parameter | Value |
|---|---|
| Analytes | miRNA-122 & Cytokeratin-18 |
| Platform | Luminex xMAP® (Validated on MAGPIX®, etc.) |
| Detection Method | PCR-Free Destina Chemistry |
| Time to Result | < 5 Hours |
| Sample Volume | To be confirmed |
| Sample Type | Serum, Plasma |
| Quantification Range | Absolute (Calibrators included) |
Performance Characteristics
Performance characteristics will be published at product launch.
Assay Procedure
Simple, Streamlined, Superior
An immunoassay-like protocol for both miRNA-122 and CK18: no PCR, one familiar platform and workflow.
1. Add Sample
2. Capturing & Hybridizing
3. Label
4. Read
Applications & Research Fields
- Pharma R&D & Drug Development
- CROs & Service Labs
- Preclinical Safety Assessment
- Clinical Trials
- Liver Toxicity (DILI) Screening
Documentation
The Product Brochure is available now. The User Manual and Safety Data Sheet (SDS) will be available at product launch.
Ready to Transform Your Liver Safety Assessment?
Our specialists are ready to discuss your testing needs.
Get in Touch
